Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: Prespecified Analysis from EXSCEL

Robert J. Mentz; Vivian P. Thompson; David Aguilar; Jasmine Choi; Stephanie M. Gustavson; Nayyar Iqbal; Alice P. Kong; Peter Öhman; Naveed Sattar; Russell S. Scott; Yee Weng Wong; Rury R. Holman; Adrian F. Hernandez

doi:10.1161/CIRCULATIONAHA.118.036811

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: Prespecified Analysis from EXSCEL

Robert J. Mentz, Vivian P. Thompson, David Aguilar, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Alice P. Kong, Peter Öhman, Naveed Sattar, Russell S. Scott, Yee Weng Wong, Rury R. Holman, Adrian F. Hernandez

Internal Medicine

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Original language	English
Pages (from-to)	2576-2578
Number of pages	3
Journal	Circulation
Volume	138
Issue number	22
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.118.036811
State	Published - Nov 27 2018

Bibliographical note

Funding Information:
EXSCEL was sponsored and funded by Amylin Pharmaceuticals Inc (San Diego, CA), a wholly owned subsidiary of AstraZeneca (Gaithersburg, MD).

Funding

EXSCEL was sponsored and funded by Amylin Pharmaceuticals Inc (San Diego, CA), a wholly owned subsidiary of AstraZeneca (Gaithersburg, MD).

Funders	Funder number
Amylin Pharmaceuticals Incorporated
AstraZeneca

Keywords

cardiovascular diseases
outcome measures
pharmacotherapy
type 2 diabetes mellitus

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.118.036811

Cite this

Mentz, R. J., Thompson, V. P., Aguilar, D., Choi, J., Gustavson, S. M., Iqbal, N., Kong, A. P., Öhman, P., Sattar, N., Scott, R. S., Wong, Y. W., Holman, R. R., & Hernandez, A. F. (2018). Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: Prespecified Analysis from EXSCEL. Circulation, 138(22), 2576-2578. https://doi.org/10.1161/CIRCULATIONAHA.118.036811

@article{f31141ca89ac40998a4eaaeaf62bba49,

title = "Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: Prespecified Analysis from EXSCEL",

keywords = "cardiovascular diseases, outcome measures, pharmacotherapy, type 2 diabetes mellitus",

author = "Mentz, \{Robert J.\} and Thompson, \{Vivian P.\} and David Aguilar and Jasmine Choi and Gustavson, \{Stephanie M.\} and Nayyar Iqbal and Kong, \{Alice P.\} and Peter {\"O}hman and Naveed Sattar and Scott, \{Russell S.\} and Wong, \{Yee Weng\} and Holman, \{Rury R.\} and Hernandez, \{Adrian F.\}",

note = "Funding Information: EXSCEL was sponsored and funded by Amylin Pharmaceuticals Inc (San Diego, CA), a wholly owned subsidiary of AstraZeneca (Gaithersburg, MD). ",

year = "2018",

month = nov,

day = "27",

doi = "10.1161/CIRCULATIONAHA.118.036811",

language = "English",

volume = "138",

pages = "2576--2578",

number = "22",

}

Mentz, RJ, Thompson, VP, Aguilar, D, Choi, J, Gustavson, SM, Iqbal, N, Kong, AP, Öhman, P, Sattar, N, Scott, RS, Wong, YW, Holman, RR & Hernandez, AF 2018, 'Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: Prespecified Analysis from EXSCEL', Circulation, vol. 138, no. 22, pp. 2576-2578. https://doi.org/10.1161/CIRCULATIONAHA.118.036811

TY - JOUR

T1 - Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease

T2 - Prespecified Analysis from EXSCEL

AU - Mentz, Robert J.

AU - Thompson, Vivian P.

AU - Aguilar, David

AU - Choi, Jasmine

AU - Gustavson, Stephanie M.

AU - Iqbal, Nayyar

AU - Kong, Alice P.

AU - Öhman, Peter

AU - Sattar, Naveed

AU - Scott, Russell S.

AU - Wong, Yee Weng

AU - Holman, Rury R.

AU - Hernandez, Adrian F.

N1 - Funding Information: EXSCEL was sponsored and funded by Amylin Pharmaceuticals Inc (San Diego, CA), a wholly owned subsidiary of AstraZeneca (Gaithersburg, MD).

PY - 2018/11/27

Y1 - 2018/11/27

KW - cardiovascular diseases

KW - outcome measures

KW - pharmacotherapy

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85058909800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058909800&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.118.036811

DO - 10.1161/CIRCULATIONAHA.118.036811

M3 - Article

C2 - 30571356

AN - SCOPUS:85058909800

SN - 0009-7322

VL - 138

SP - 2576

EP - 2578

JO - Circulation

JF - Circulation

IS - 22

ER -

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: Prespecified Analysis from EXSCEL

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this